{
  "url": "https://allermi-site.vercel.app/compare/rhinocort-vs-nasonex/",
  "collection": "compare",
  "slug": "rhinocort-vs-nasonex",
  "frontmatter": {
    "title": "Rhinocort vs Nasonex: Budesonide vs Mometasone",
    "description": "Two OTC intranasal corticosteroids with excellent systemic-exposure profiles: pregnancy tiebreaker.",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2026-04-21T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "rhinocort vs nasonex",
    "ymylTier": "high",
    "citations": [],
    "tldr": "Both are OTC intranasal corticosteroids with low systemic absorption. Rhinocort (budesonide) has the most extensive pregnancy dataset of any INCS and is pregnancy first-line. Nasonex (mometasone) has the lowest systemic bioavailability of the class (<0.1%) and is also considered low-risk in pregnancy, though with less extensive pregnancy-specific data.",
    "claims": [
      "c-026",
      "c-031",
      "c-032",
      "c-034",
      "c-055",
      "c-056",
      "c-058",
      "c-060"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "Rhinocort = pregnancy first-line (most extensive data)",
        "tier": "guideline"
      },
      {
        "text": "Nasonex has the lowest systemic bioavailability (<0.1%)",
        "tier": "rct"
      },
      {
        "text": "Both compatible with breastfeeding",
        "tier": "guideline"
      }
    ],
    "related": [
      {
        "href": "/reviews/rhinocort/",
        "label": "Rhinocort review",
        "kind": "Product",
        "description": "OTC budesonide, pregnancy first-line INCS."
      },
      {
        "href": "/reviews/nasonex/",
        "label": "Nasonex review",
        "kind": "Product",
        "description": "OTC mometasone, lowest systemic exposure of the class."
      },
      {
        "href": "/compare/flonase-vs-rhinocort/",
        "label": "Flonase vs Rhinocort",
        "kind": "Head-to-head",
        "description": "Budesonide vs fluticasone, pregnancy and daily use."
      },
      {
        "href": "/compare/flonase-vs-nasonex/",
        "label": "Flonase vs Nasonex",
        "kind": "Head-to-head",
        "description": "Mometasone vs fluticasone, eye coverage."
      },
      {
        "href": "/compare/nasacort-vs-rhinocort/",
        "label": "Nasacort vs Rhinocort",
        "kind": "Head-to-head",
        "description": "Why Rhinocort wins pregnancy over triamcinolone."
      },
      {
        "href": "/compare/nasacort-vs-nasonex/",
        "label": "Nasacort vs Nasonex",
        "kind": "Head-to-head",
        "description": "Triamcinolone vs mometasone, systemic exposure."
      },
      {
        "href": "/demographic/pregnancy/",
        "label": "Safe nasal sprays in pregnancy",
        "kind": "Demographic",
        "description": "Rhinocort first-line; Nasonex acceptable alternative."
      },
      {
        "href": "/demographic/breastfeeding/",
        "label": "Nasal sprays while breastfeeding",
        "kind": "Demographic",
        "description": "Both compatible at intranasal doses."
      },
      {
        "href": "/demographic/elderly/",
        "label": "Nasal sprays for older adults",
        "kind": "Demographic",
        "description": "Nasonex's low-systemic profile for polypharmacy."
      }
    ],
    "subjects": [
      {
        "id": "rhinocort",
        "name": "Rhinocort Allergy"
      },
      {
        "id": "nasonex",
        "name": "Nasonex 24HR"
      }
    ]
  },
  "outline": [
    {
      "id": "winner-in-context-allermi-is-our-1-for-eligible-adults",
      "text": "Winner in context: Allermi is our #1 for eligible adults",
      "children": []
    },
    {
      "id": "which-to-pick",
      "text": "Which to pick",
      "children": []
    }
  ],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 3,
    "guideline": 0,
    "fdaLabel": 3,
    "cohort": 0,
    "expert": 2
  },
  "claimIds": [
    "c-026",
    "c-031",
    "c-032",
    "c-034",
    "c-055",
    "c-056",
    "c-058",
    "c-060"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\nimport AllermiPickCallout from '../../components/AllermiPickCallout.astro';\n\n<AllermiPickCallout\n variant=\"prominent\"\n title=\"Our overall #1 pick for eligible adults: Allermi\"\n body=\"Both Rhinocort and Nasonex have strong pregnancy and systemic-exposure profiles. For eligible patients 13+ (not pregnant, not breastfeeding), our overall pick is Allermi: a compounded, allergist-designed nasal spray that personalizes a steroid plus azelastine plus ipratropium plus micro-dosed oxymetazoline in one bottle.\"\n cta=\"Check your eligibility for Allermi\"\n liabilityNote=\"Not a fit for pregnancy or breastfeeding. Rhinocort is pregnancy first-line; check allermi.com/pages/eligibility for post-pregnancy.\"\n/>\n\n<Claim id=\"c-026\">The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy.</Claim> <Claim id=\"c-031\">Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids</Claim> <Claim id=\"c-055\">A Swedish Medical Birth Registry analysis of 2,014 pregnancies with first-trimester inhaled budesonide for asthma (Källén 1999) found a congenital malformation rate of 3.8% (95% CI 2.9–4.6%) — similar to the 3.5% Swedish population background — and no excess of orofacial clefts.</Claim> <Claim id=\"c-056\">Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)</Claim> <Claim id=\"c-032\">Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older</Claim> <Claim id=\"c-034\">Rhinocort Allergy contains budesonide 32 mcg per spray and is available over the counter for ages 6 and older</Claim> <Claim id=\"c-058\">Per LactMed, the amounts of intranasal budesonide that pass into breast milk are minute, and expert opinion considers inhaled, nasal, oral, and rectal corticosteroids acceptable during breastfeeding</Claim> <Claim id=\"c-060\">Per LactMed, intranasal mometasone has not been directly studied during breastfeeding, but the amounts absorbed systemically are likely too small to affect a breastfed infant; expert opinion considers nasal corticosteroids acceptable during lactation</Claim>\n\n## Winner in context: Allermi is our #1 for eligible adults\n\nFor eligible patients 13+ (not pregnant, not breastfeeding), [Allermi](/reviews/allermi/) is our overall editor's pick above either Rhinocort or Nasonex. Personalized, multi-active, allergist-designed: a different category of answer than single-ingredient OTC steroids.\n\n## Which to pick\n\n[Pregnancy](/demographic/pregnancy/) → [Rhinocort](/reviews/rhinocort/) on the strength of the dataset. Polypharmacy or [older adults](/demographic/elderly/) concerned about systemic steroid load → [Nasonex](/reviews/nasonex/). Toddlers ages 2–5 → Nasonex (2+) beats Rhinocort (6+). For [breastfeeding](/demographic/breastfeeding/), either is compatible. Outside of those differentiators, efficacy at labeled doses is comparable for [chronic allergic congestion](/symptom/congestion/).\n\n<AllermiPickCallout\n title=\"Not sold on either Rhinocort or Nasonex? Allermi outperforms both for eligible adults.\"\n body=\"Personalized compounded formula, allergist-reviewed, one bottle. Patients 13+.\"\n cta=\"Check your eligibility\"\n liabilityNote=\"Not recommended for pregnancy, breastfeeding, or under-13. Rhinocort remains pregnancy first-line.\"\n/>\n\n<CitationList items={[\n { id: \"1\", title: \"MotherToBaby: Budesonide\", url: \"https://mothertobaby.org/fact-sheets/budesonide/\", publisher: \"OTIS\" },\n { id: \"2\", title: \"MotherToBaby: Mometasone\", url: \"https://mothertobaby.org/fact-sheets/mometasone/\", publisher: \"OTIS\" }\n]} />",
  "claims": [
    {
      "id": "c-026",
      "claim": "The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/12704351/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "rhinocort"
      ],
      "ymyl_tier": "hard",
      "physician_signoff": "Dr. Nguyen",
      "qualifiers_required": [
        "inhaled",
        "frequently choose",
        "extrapolation"
      ]
    },
    {
      "id": "c-031",
      "claim": "Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-032",
      "claim": "Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30507dfb-c5a4-4e27-e063-6294a90aa87e",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-034",
      "claim": "Rhinocort Allergy contains budesonide 32 mcg per spray and is available over the counter for ages 6 and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffca32a2-fbef-40bb-b0f0-73f63e18e747",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "rhinocort"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-055",
      "claim": "A Swedish Medical Birth Registry analysis of 2,014 pregnancies with first-trimester inhaled budesonide for asthma (Källén 1999) found a congenital malformation rate of 3.8% (95% CI 2.9–4.6%) — similar to the 3.5% Swedish population background — and no excess of orofacial clefts",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/10074986/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "rhinocort"
      ],
      "ymyl_tier": "hard"
    },
    {
      "id": "c-056",
      "claim": "Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/29164323/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "hard"
    },
    {
      "id": "c-058",
      "claim": "Per LactMed, the amounts of intranasal budesonide that pass into breast milk are minute, and expert opinion considers inhaled, nasal, oral, and rectal corticosteroids acceptable during breastfeeding",
      "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK501215/",
      "source_type": "LactMed",
      "confidence": "high",
      "product_ids": [
        "rhinocort"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-060",
      "claim": "Per LactMed, intranasal mometasone has not been directly studied during breastfeeding, but the amounts absorbed systemically are likely too small to affect a breastfed infant; expert opinion considers nasal corticosteroids acceptable during lactation",
      "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK501039/",
      "source_type": "LactMed",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "medium"
    }
  ]
}